Monoclonal antibodies to target asthma

Research output: Contribution to journalArticle

Abstract

Current therapies for asthma are aimed at controlling disease symptoms. For the majority of asthmatics glucocorticoid-based inhaled anti-inflammatory therapy is effective. However, a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses underlying the pathogenesis of asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IgE, IL-4 and IL-5.
Original languageEnglish
Pages (from-to)6-8
Number of pages3
JournalBiotech Inernational
Volume22
Issue number2
Publication statusPublished - 2010

Fingerprint

Asthma
Monoclonal Antibodies
Antibodies, Monoclonal, Humanized
Interleukin-5
Therapeutics
Interleukin-4
Immunoglobulin E
Glucocorticoids
Anti-Inflammatory Agents
Pharmaceutical Preparations

Cite this

Monoclonal antibodies to target asthma. / Walsh, Garry M.

In: Biotech Inernational, Vol. 22, No. 2, 2010, p. 6-8.

Research output: Contribution to journalArticle

@article{205ad1979c6e47a3b2073dd2edce5500,
title = "Monoclonal antibodies to target asthma",
abstract = "Current therapies for asthma are aimed at controlling disease symptoms. For the majority of asthmatics glucocorticoid-based inhaled anti-inflammatory therapy is effective. However, a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses underlying the pathogenesis of asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IgE, IL-4 and IL-5.",
author = "Walsh, {Garry M}",
year = "2010",
language = "English",
volume = "22",
pages = "6--8",
journal = "Biotech Inernational",
number = "2",

}

TY - JOUR

T1 - Monoclonal antibodies to target asthma

AU - Walsh, Garry M

PY - 2010

Y1 - 2010

N2 - Current therapies for asthma are aimed at controlling disease symptoms. For the majority of asthmatics glucocorticoid-based inhaled anti-inflammatory therapy is effective. However, a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses underlying the pathogenesis of asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IgE, IL-4 and IL-5.

AB - Current therapies for asthma are aimed at controlling disease symptoms. For the majority of asthmatics glucocorticoid-based inhaled anti-inflammatory therapy is effective. However, a subset of patients remains symptomatic despite optimal treatment creating a clear unmet medical need. Biopharmaceutical approaches may identify small molecules that target key cells and mediators that drive the inflammatory responses underlying the pathogenesis of asthma. Significant areas of drug development include humanised monoclonal antibodies (mAb) for asthma therapy including those against IgE, IL-4 and IL-5.

M3 - Article

VL - 22

SP - 6

EP - 8

JO - Biotech Inernational

JF - Biotech Inernational

IS - 2

ER -